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Abstract
Metabolic syndrome (MetS), i.e., meeting criteria for any three of the following: hyperglycemia, 
hypertension, hypertriglyceridemia, low high-density lipoprotein and/or abdominal obesity, is 
associated with negative health outcomes. For example, MetS negatively impacts cognition; 
however, less is known about incremental MetS risk, i.e., meeting 1 or 2 as opposed to 3 or more 
criteria. We hypothesized incremental MetS risk would negatively contribute to cognition and 
relevant neuroanatomy, e.g., memory and hippocampal volumes, and that this risk extends to 
affective functioning. 119 non-demented/non-depressed participants (age=60.1±12.9; ~50% 
African American) grouped by incremental MetS risk–no (0 criteria met), low (1–2 criteria met), 
or high (3+ criteria met)–were compared across cognition, affect and relevant neuroanatomy using 
multivariable linear regressions. Exploratory analyses, stratified by race, consider the role of 
health disparities in disease severity of individual MetS component (e.g., actual blood pressure 
readings) on significant results from primary analyses. Incremental MetS risk contributed to 
depressive symptomatology (no<low<high), learning and memory performance (no>low=high) 
after controlling for age, race (n.s.) and IQ. Different indices of disease severity contributed to 
different aspects of brain structure and function by race providing empirical support for future 
studies of the impact distinct health disparities in vascular risk have on brain aging. MetS 
compromised mood, cognition and hippocampal structure with incremental risk applying to some 
but not all of these outcomes. Care providers may wish to monitor a broader spectrum of risk 
including components of MetS like blood pressure and cholesterol levels when considering brain-
behavior relationships in adults from diverse populations.
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1. INTRODUCTION
Vascular risk factors like hypertension and diabetes likely contribute to Alzheimer’s disease 
(AD) either through non-amyloid related neuropathology and/or via a cascade of events that 
ultimately leads to amyloid-related alterations [1]. Regardless of mechanism, the negative 
contribution from vascular risk factors on brain aging lowers the threshold for developing 
AD [2–4]. When considered within the context of significant declines in US mortality rates 
from cardiovascular disease (CVD) and stroke [5], it appears older adults with CVD and 
associated vascular risks are living longer but they are not necessarily living well. This is 
particularly true in the African American (AA) population. Notably, AAs are over twice as 
likely to have diabetes (OR=2.58) and almost twice as likely to have high blood pressure 
(OR=1.88) when compared to CAs [6]. Additionally, AAs have significantly higher rates of 
uncontrolled vascular risk (58% versus 47%) than Caucasian Americans (CAs), regardless 
of socioeconomic status [7] or weight [8] - rates that are not declining despite declines in 
other populations [8]. Thus, at least half of the US population is at risk for increased 
vascular-related neuropathology leading to cognitive decline and dementia including AD 
[9]. Although AAs are disproportionately affected by elevated and often uncontrolled 
vascular risk, particularly diabetes and hypertension, and its negative impact on cognition 
and brain aging, less is known about how such risk manifests within the context of other 
vascular comorbidities. Gaining additional knowledge about coexisting disease states on 
brain aging may facilitate living well, not just living longer with CVD and associated 
vascular risk.
Investigating comorbid vascular risk as it relates to brain aging using known symptom 
clusters that are linked to CVD and associated vascular risks like hypertension and diabetes 
may highlight clinical profiles to monitor and individual symptoms to remediate both within 
and across populations disproportionately affected by these age-related disease states. 
Individuals with three or more of the following cluster of symptoms, including HTN, and 
hyperglycemia as well as hypertriglyceridemia, low high-density lipoprotein (HDL) levels 
and/or abdominal obesity are known to have Metabolic Syndrome (MetS) [10]. [10]The 
broad spectrum provided by symptom clustering in MetS and/or disease severity of 
individual MetS components (e.g., actual blood pressure readings) may help determine 
targets to monitor and symptoms to manage in order to facilitate successful brain aging. 
Furthermore, exploring if and how health disparities between AA and CA populations 
(groups known to have different prevalence rates and adequate control of vascular risk 
factors) may impact these profiles could better individualize treatment monitoring and 
management.
Memory, executive function and attention/information processing deficits are often 
associated with individual vascular risk factors (e.g., [11]) and sometimes, but not always 
[12], observed in individuals meeting three or more criteria for MetS [13–15]. Equivocal 
results in MetS may be due, in part, to the fact that a limited number of MetS studies of 
cognition (e.g., [16]) ensure that their healthy control comparison group did not meet any 
(i.e., no) MetS criteria. This leaves in doubt whether meeting one or two but not three or 
more criteria for MetS has an impact on cognitive functioning [15]. Others debate the 
importance of meeting criteria for MetS [17] versus displaying significant disease severity 
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across individual component parts [18] when investigating cognitive impairment. Thus, 
incremental MetS risk may be as important to cognitive functioning as MetS and/or 
individual vascular diagnoses when investigating brain aging in affected individuals.
These issues extend beyond cognition to encompass affect, an understudied area, 
particularly for AA populations [19, 20]. For example, there is a large literature linking 
select vascular diagnosis like Type 2 diabetes with depression [21]. In contrast, some [22, 
23], but not all [24] MetS studies suggests increasing depressive symptomatology in adults 
with MetS. This may be due, in part, to the fact that there may be a more selective 
relationship between depression and disease severity of individual MetS components, e.g., 
triglyceride levels, than between depression and MetS per se [25]. More work should be 
done investigating affective functioning as it relates to conflicting results suggesting MetS 
as well as individual MetS components may play a role in depressive symptomatology.
We will address these gaps in the literature by evaluating cognitive as well as depressive 
symptomatology as it relates to meeting an increasing number of MetS criteria. We will also 
explore the role that health disparities in individual component severity may play in these 
profiles across AA and CA cohorts. Thus, our primary study aim is to provide information 
on the impact of meeting increasing MetS criteria regardless of race. We hypothesize that 
incremental MetS risk as defined by increasing symptom clusters (0 versus 1–2 versus 3+) 
will contribute to decreases in memory and executive functioning such that individuals with 
3+ MetS risk will perform worse than individuals with 1–2 MetS risk who will perform 
worse than individuals with no MetS risk. We further hypothesize that relevant 
neuroanatomical volumes (e.g., medial temporal regions known to contribute to memory 
performance) will show similar profiles of MetS involvement such that individuals with 3+ 
MetS risk will have the smallest volumes while individuals with 1–2 MetS risk will show 
intermediate volumes between the 3+ and 0 risk groups. We also hypothesize that this 
profile of incremental risk, i.e., 3+ greater than 1–2 greater than 0, will also be seen for 
levels of depressive symptomatology. Lastly, we will explore the impact of health disparities 
in individual MetS component severity on significant results from our primary study aim to 
provide hypothesis generating evidence regarding differential contributions of individual 
vascular risk factors affiliated with MetS for AA versus CA as it relates to brain structure 
and function.
2. MATERIALS AND METHODS
2.1 Participants
Data collection was part of a larger research program on depression and Type 2 diabetes at 
the University of Illinois at Chicago (UIC) approved by the UIC Institutional Review Board 
and conducted in accordance with the Declaration of Helsinki. Volunteers age 30 and older 
were recruited via community outreach and underwent a preliminary telephone screen. 
Exclusion criteria consisted of current or past history of any of the following: neurological 
disorder (i.e., dementia, stroke, seizure, etc.), head injury or loss of consciousness, an Axis I 
disorder (e.g., major depression, bipolar disorder), substance abuse or dependence, 
psychotropic medication use.
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After passing the telephone screen, participants were scheduled for a more detailed 
screening for final inclusion/exclusion determination that included a Mini-Mental State 
Examination (MMSE) [26] and the Structured Clinical Interview for DSM-IV (SCID). A 
trained research assistant administered these measures and a board certified/eligible 
(AK/OA) psychiatrist completed the 17-item Hamilton Depression Rating Scale (HDRS) 
[27]. Raters were blind to telephone screen information. All subjects were native English 
speakers, had an MMSE≥24, an absence of psychiatric symptoms based on the SCID, and a 
HDRS≤8. Two individuals had an MMSE<26; results did not change after excluding them; 
therefore, they remained in the sample. It is important to note that our cut-off scores for 
depression and cognition were not taken from the same assessment tools used to derive 
variables of interest for the analyses outlined below. This, combined with the fact that the 
MMSE is a gross measure of overall cognitive functioning, decreased the likelihood that the 
distribution of our variables of interest were unduly truncated by excluding participants with 
evidence of frank depression or dementia.
The final sample included 119 individuals (65 women; ~50% AA) approximately 60 years 
old (mean=60.1±12.9; range=30–89) with roughly 15 years of education (mean=14.9±2.7), 
MMSE scores of 28.8±1.3 and HDRS scores below cut-off for significant depressive 
symptomatology (1.2±1.5).
2.2 Vascular Assessment and Metabolic Syndrome Risk Evaluation
Laboratory testing from non-fasting blood draws documented levels of health related 
variables (e.g., cholesterol and glucose levels). It should be noted that levels of triglycerides 
and HDL are minimally affected by normal food intake [28] and as predictive of 
cardiovascular risk as fasting blood draws [28, 29]. The blood draw also provided a measure 
of hemoglobin A1c (hA1c), an important indicator of average blood sugar control over the 
past 2–3 months that is less affected by normal food intake [30]. The Cumulative Illness 
Rating Scale (CIRS) quantified the state and severity of current and past medical disorders.
MetS risk was determined based on International Diabetes Federation (IDF) criteria [31] 
which is in line with National Cholesterol Education Program’s Adult Treatment Panel III 
report [32] with the exception of the classification of central obesity [33] as outlined below. 
Participants were given a point for every criterion met for blood pressure≥130/85mm/Hg, 
glucose≥100mg/dL, triglyceride≥150mg/dL, HDL cholesterol<40mg/dL (men) or 
<50mg/dL (women), and body mass index (BMI) >30 kg/m2. Although IDF criteria focus 
on central obesity, these criteria also state that if BMI is greater than 30 kg/m2, central 
obesity is presumed [31]. Medication was not considered in determining the number of 
MetS criteria met and discussed further in the limitations section of this manuscript. 
Additionally, IDF criteria allows for a diagnosis of Type 2 diabetes to count toward MetS 
totals in the absence of elevated glucose; however, we relied on glucose levels as opposed to 
diagnosis given some diabetics may be unduly penalized despite adequate control of their 
blood sugar. These instances were expected to be low given that approximately half of all 
AAs (58%) and CAs (47%) have uncontrolled vascular risk [7, 8] contributing a point 
toward MetS regardless. Supplemental tables provided as part of this submission show that 
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even when including a diagnosis of diabetes as a criterion toward MetS, our results profile 
remained the same (see Supplemental Materials online).
The total number of MetS criteria met was categorized to reflect incremental risk: no risk=0 
criteria met, low risk=1–2 criteria met, and high risk=3 or more (3+) criteria met. We re-
grouped individuals based on non-fasting glucose or ‘random’ blood draw cut-offs for 
glucose (≥200mg/dL) – the American Diabetes Association recommended cut-off for a 
diagnosis of diabetes and the cut-off for non-fasting blood draws used in previous MetS 
studies [34] – to ensure that our non-fasting measures of glucose did not unduly bias our 
results; as noted in the results below, they did not.
2.3 Neuropsychological and Neuroimaging Procedures
2.3.1 Neuropsychological Assessment—The neuropsychological assessment was 
conducted by a trained research assistant blind to MetS group and included a subjective 
measure of depressive symtomatology, the Center for Epidemiological Study of Depression 
scale (CESD) [35]. It also included standardized measures of predicted verbal intelligence 
(pVIQ; Wechsler Test of Adult Reading) and composite measures of Learning (LRN), 
Memory (MEM), Recognition Memory (REC), Attention/Information Processing (AIP) and 
executive functioning (EF). LRN comprised total recall for Trials 1–5 of the California 
Verbal Learning Test-II (CVLT-II) [36] and immediate free recall from the Wechsler 
Memory Scale-III (WMS-III; Logical Memory-I and Visual Reproduction-I) [37]. MEM 
consisted of CVLT-II long delay free recall and WMS-III delay free recall (Logical 
Memory-II and Visual Reproduction-II). REC consisted of recognition memory for Logical 
Memory and Visual Reproduction as well as a discriminability index from the CVLT-II [i.e., 
1−(false positive errors+misses)/48)*100; max=100)]. AIP comprised the Stroop Color and 
Word raw scores, Trail Making Test (TMT) Part A time-to-completion and Wechsler Adult 
Intelligence Scale-III (WAIS-III) Digit-Symbol Coding raw score [38]. EF consisted of 
Category Switching total accuracy from the Delis-Kaplan Executive Function System batter 
[39], TMT-B time-to-completion, Stroop Interference Score, WAIS-III [38] Digit Span 
Backwards raw score and Self-Ordered Pointing Task total errors [40].
Raw scores were transformed to z-scores, coded so high scores reflected good performance 
then averaged to produce a mean score for each cognitive domain. Cronbach’s alpha 
determined how well variables measured each latent construct; all values were considered 
good indicators of unidimensional latent constructs (α: LRN=.79; MEM=.75; REC= .63; 
AIP=.82; EF=.73).
2.3.2 Neuroimaging Data Acquisition—Whole brain MRI were acquired using Philips 
Achieva 3.0T scanner (Philips Medical Systems, the Netherlands) with an 8-element 
sensitivity encoding head-coil. Participants were positioned comfortably in the scanner, 
fitted with earplugs and instructed to remain still throughout the scan. Pads minimized head 
motion. High-resolution three-dimensional axial T1-weighted images were acquired with 
MPRAGE (FOV=240mm; contiguous slices=134; TR/TE=8.4/3.9ms; flip angle=8°; voxel 
size=1.1×1.1×1.1mm).
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Forty-six participants did not have imaging leaving 84 with T1-weighted imaging. Reasons 
for missing data included claustrophobia(n=12); BMI(n=3); metallic implants(n=3); study 
withdrawal(n=3); lost to follow-up(n=1); repeat cancellations(n=3); data not acquired(n=9), 
lost(n=5), unavailable(n=3) or poor quality(n=1); (3=unknown). Characteristics and MetS 
groupings of this smaller sample remained unchanged from those reported for the larger 
sample. Compared to the 46 individuals without MRI, participants with MRI were older 
(61.4±12.2 versus 56.9±13.8; p=.054) and had higher pVIQs (106.3±14.1 versus 
100.8±12.1; p=.03).
2.3.3 Neuroimaging Data Processing—Results were analyzed on an independent 
workstation (VMware, http://www.vmware.com/; Ubuntu platform, http://
www.ubuntu.com/). It should be noted that prior to inclusion in this study, all scans were 
examined for space occupying and other focal lesions, including stroke. Eight potential 
participants were excluded from consideration; however, all subjects included in our 
analyses were free of any gross abnormalities. T1-weighted images were used to generate 
label maps using FreeSurfer for volumetric segmentation [41]. For this study, specific 
regions of interest (ROIs) within temporal and prefrontal cortices were calculated (right + 
left hemisphere) controlling for intracranial volume. Temporal ROIs included the 
hippocampus, entorhinal cortex, parahippocampal gyrus, and fusiform gyrus. Prefrontal 
ROIs included the superior, middle, and inferior prefrontal cortices and the orbitofrontal 
cortex. These ROIs were chosen given their known importance to memory and/or executive 
functioning [40, 42–44].
2.4 Statistical Analyses
Demographics were evaluated using analysis of variance (ANOVA) for continuous variables 
and chi-square for categorical variables. We used multivariable linear regression analysis to 
examine the association of increasing MetS criteria (no, low, and high) with depressive 
symptomatology, cognitive functioning, and relevant neuroanatomy as dictated by results of 
the cognitive analyses. All analyses were adjusted for age, race, and IQ. For cognitive 
outcomes, we also controlled for depressive symptomatology given its association with 
CVD as well as cognition [45, 46]. Given sex differences in brain morphometry [47], sex 
was an additional covariate for neuroanatomical outcomes. Given we were testing pre-
specified hypotheses, we did not correct for multiple comparisons in our analyses. 
Furthermore, correcting for multiple exposures would have decreased our power to detect 
true associations and increase the false negative rate [48].
As warranted by the results of our first set of analyses, a second set of regression modeling 
was conducted to investigate the impact of individual MetS component disease severity (i.e., 
glucose, HDL, and triglyceride levels; blood pressure; BMI) on behavioral and relevant 
neuroanatomical outcomes significant for the entire group stratified by race to explore if the 
differential profiles of vascular risk known to exist for CAs and AAs also exerted their 
influence on associated behavioral and/or neuroanatomical profiles. We also considered 
hA1c in our severity analyses, given it provides more long-term information regarding 
control of blood sugar and diabetes. Severity metrics were only considered in the models if 
they were found to be significantly correlated with the outcome of interest at p<0.05. 
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Forward and backward selection procedures (performed manually) were used to determine 
the best-fitting and most parsimonious models. Analyses were performed using SASv9.4 
(SAS Institute Inc, Cary, NC).
3. RESULTS
Groups differed by age [F(2,118)=3.4, p=.04] and pVIQ [F(2,118)=5.6, p=.005]. Thus, 
individuals at no MetS risk, i.e., meeting 0 criteria, were younger than any other group 
(no<low=high; p’s≤.04) and individuals meeting 0, 1 or 2 MetS criteria had higher pVIQ 
than individuals meeting 3+ MetS criteria (no=low>high; p’s≤.01). There were no 
significant differences on any other demographic variables (Table 1).
As previously stated, our sample was taken from a larger study of individuals with and 
without Type 2 diabetes. The percentage of our sample with Type 2 diabetes (men=20%; 
women=21%) was commensurate with percentages reported for the State of Illinois (23.8%) 
[49]. As expected, however, the presence and duration of diabetes was significantly different 
between MetS groups (p-values<0.001). Individuals in the high risk or 3+ MetS group 
showed the highest levels of diabetes (80% of the 3+ group had diabetes) and for the longest 
duration (Table 1) compared to individuals in the low or no risk categories. Furthermore, 
hA1c levels were significantly different [F(2,118)=19.6, p<.001] such that individuals 
meeting 3+ criteria showed the highest levels followed by individuals meeting 1–2 criteria 
followed by individuals meeting no criteria (i.e., high>low>no; p-values≤0.05). Overall 
illness burden as measured by the CIRS was significantly different between groups 
[F(2,118)=159.3, p<0.001] such that increasing MetS criteria equated to increasing CIRS 
(no<low<high; p-values≤0.003).
3.1 COGNITIVE DOMAINS
As hypothesized, incremental risk based on meeting an increasing number of MetS criteria 
was significantly associated with LRN and MEM, with marginal trends seen for EF (Table 
2). There were no significant results for AIP or REC. Unlike our hypothesis, however, 
individuals at no risk outperformed individuals at either low (1–2 MetS criteria met) or high 
(3+ MetS criteria met) risk across LRN and MEM. When we used non-fasting glucose cut-
off criteria to create MetS criteria groups, results were similar.
3.2 NEUROANATOMY
Despite significant correlations between our temporal ROIs and LRN and MEM composite 
z-scores – with the exception of the entorhinal cortex (Table 3), increasing MetS criteria did 
not contribute to structural volumes associated with our significant learning and memory 
findings, i.e., hippocampal, parahippocampal, entorhinal and fusiform volumes. When we 
used non-fasting glucose cut-off criteria to create MetS groups to ensure that our non-fasting 
measures of glucose did not unduly bias our results (Results Section 2.2), results revealed 
that increasing MetS criteria did contribute to hippocampal volumes. Thus, individuals 
meeting 1–2 MetS criteria had smaller hippocampal volumes (B=−0.0007, SE=0.0003, 
p=0.04) than individuals meeting no MetS criteria. Individuals meeting 3+ MetS criteria had 
smaller hippocampal volumes than individuals meeting no MetS criteria; however, this 
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result was not significant p=0.07. Given that fasting/non-fasting cut-off criteria resulted in 
discrepant results, we did not conduct exploratory analyses stratified by race.
3.3 DEPRESSIVE SYMPTOMATOLOGY
As hypothesized, incremental risk groupings were a significant predictor of depressive 
symptomatology (Table 2). Controlling for pVIQ, age and race (not a significant covariate in 
this model), individuals at high risk, i.e., meeting 3+ MetS criteria, reported more depressive 
symptoms than individuals with low (1–2 MetS criteria met) or no risk. Individuals meeting 
1–2 MetS criteria reported more depressive symptoms than individuals at no risk after 
adjustment for pVIQ, age and race; however, this result was not significant p=0.08. When 
we used non-fasting glucose cut-off criteria to create MetS criteria groups, results were 
similar.
3.4 EXPLORATORY ANALYSES STRATIFIED BY RACE
When we stratified our sample by race, increasing diastolic blood pressure significantly 
contributed to both LRN (B=−0.01, SE=0.07, p=0.089) and MEM (B=−0.01, SE=0.001, 
p=0.04) in the CA cohort; increasing triglyceride levels (B=−0.002, SE=0.001, p=0.056) 
also contributed to MEM scores in the CA cohort. In contrast, results revealed the 
importance of elevated glucose (B=−0.003, SE=0.01, p=0.009) on LRN and increasing 
systolic blood pressure on MEM (B=−0.01, SE=0.048, p=0.001) within the AA cohort.
When we stratified our sample by race, results revealed the importance of increasing hA1c 
(B=2.19, SE=0.75, p=0.004) and triglyceride levels (B=0.02, SE=0.008, p=0.003) to CESD 
scores in the CA group. There were no significant contributes to CESD scores within the 
AA cohort as it related to MetS component disease severity.
4. DISCUSSION
As hypothesized, the presence of metabolic risk factors compromised memory and related 
hippocampal structures as well as mood when compared to the absence of metabolic risk 
factors. Apart from increasing MetS criteria being associated with increasing depressive 
symptoms, meeting 3 or more MetS criteria did not distinguish between alterations in 
cognitive functioning seen when only 1–2 MetS criteria were met. In fact, the 
neuropsychological profile associated with meeting only 1–2 MetS criteria, may be as 
detrimental as the high risk category. More specifically, results consistently revealed 
alterations in learning and memory on the order of a 0.5 standard deviation unit decrement 
in these cognition domains when individuals meeting 1–2 or 3 or more MetS criteria were 
compared to those meeting no (0) criteria. This suggests that the cognitive similarities of 
meeting 1–2 MetS criteria versus 3 or more may explain some of the null results reported in 
previous studies of MetS and cognition when the non-MetS comparison group consisted of 
individuals not meeting 3 or more criteria for MetS [50] as opposed to individuals not 
meeting any criteria for MetS [16]. These results may also suggest that i) once an individual 
meets a particular threshold of metabolic risk, there is a ‘plateau’ effect for select cognitive 
functions such that increasing risk factors no longer increase cognitive compromise and ii) 
this threshold may be as low as 1–2 vascular risk factors.
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Our investigation of encoding (learning), retrieval (memory), and recognition suggests that it 
is the first two of these cognitive processes, i.e., encoding and retrieval that are negatively – 
and equally – impacted by any MetS risk in our cross-sectional study. Poor performance 
during spontaneous recall is often facilitated by recognition testing in individuals with 
vascular-related cognitive deficits regardless of dementia [51, 52]. Results in our sample of 
Caucasian and African Americans corroborate and extend this finding to a non-depressed, 
non-demented cohort of vasculopaths. Additionally, the fact that individuals meeting 
increasing MetS criteria showed smaller hippocampal volume than individuals meeting no 
MetS criteria but no differences in executive function tasks suggest that recognition memory 
may have been facilitated by intact prefrontal circuitry known to be associated with these 
cognitive functions regardless of race. Future studies incorporating more in-depth 
neuroimaging techniques are needed to adequately address our preliminary conclusions 
although there are some existing gross morphometric studies that support this assertion in 
other vascular, e.g., diabetic, populations [53, 54].
Results for learning, memory and hippocampal integrity from our primary analyses, speak to 
the negative role co-existing disease states may play on brain behavior relationships [55]. 
Vascular risk factors like hypertension, diabetes and dyslipidemia – facets of which 
contribute to MetS criteria – increase inflammation and decrease blood brain barrier 
integrity [56, 57]. Likewise, they make the brain more vulnerable to other pathologies, most 
notably white matter and amyloid-related alterations [58]. Using amyloid as an example, 
vascular risk factors directly lower blood flow thus diminishing a-beta peptide clearance 
from the CNS which in turn increases amyloid accumulation in brain. These general 
discussions of the vascular risk spectrum represented by MetS says nothing of the role 
insulin and the insulin signaling transporter system – key players in glucose levels and 
diabetes as well as dyslipidemia associated with MetS – play in hippocampal dysfunction 
both structurally and functionally [59]. Thus, our association between learning and memory 
and relevant neuroanatomy as well as the role of increasing MetS on hippocampal structural 
integrity suggests that more work needs to be done investigating comorbid vascular risk as it 
relates to brain aging using known symptom clusters that are linked to insulin and insulin 
resistance.
Our exploratory analyses of the specific contributions of individual MetS component’s 
disease severity by race, revealed differential profiles of statistically significant disease 
predictors based on the behavior assessed. Thus, when stratified by race, distinct patterns of 
individual disease involvement selectively contributed to depressive symptoms as well as 
learning and memory. More specifically, for every unit increase in hA1c, CAs showed a 2.2 
point increase in depressive symptomatology. While triglycerides also contributed to 
depressive symptomatology in this group, replicating previous work [25] the unit increase in 
the current study was marginal even when equated for meaningful change per measurement 
to hA1C; e.g., a 50 unit increase in triglyceride levels that equates to a move from borderline 
high (150 mg/dL) to high (200 mg/dL) only resulted in a 1 point increase in depressive 
symptomatology. No one individual disease contributed to depressive symptomatology in 
the AA group. In contrast, disease severity differentially contributed to learning and memory 
scores for Caucasian and African Americans. While the more long-term indicator of blood 
sugar control, hA1c, predicted affective functioning in CAs, the more short-term, daily 
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indicator of blood sugar control, glucose, predicted cognitive functioning in AAs. 
Additionally, diastolic blood pressure contributed to learning performance in the Caucasian 
group and also predicted memory performance in this same group along with levels of 
triglycerides. Only systolic blood pressure predicted memory performance in the AA group. 
It should be noted, however, that the standard deviation unit decrements associated with a 
unit change in any of these predictors from pre-clinical to diagnostic states (e.g, a 25 unit 
shift in glucose or a 10–20 unit shift in systolic or diastolic blood pressure) were small – less 
than one-fifth of a standard deviation. Thus, while these preliminary results revealed unique 
aspects of disease severity as contributors to learning and memory by race, the extent to 
which these specific aspects of MetS are driving these cognitive profiles is unclear and 
warrant further exploration in a larger sample.
Regardless of clinical impact, our exploratory analyses regarding disease severity of 
individual MetS components provide hypothesis generating evidence for future studies 
investigating how such things as glucose, blood pressure and triglycerides may be 
differentially influencing cognition by race. For example, we investigated systolic and 
diastolic pressure as distinct and continuous variables; as a result, the relationship between 
these metrics and brain function was not constant and may reflect different manifestations 
known to occur in diverse populations [60]. Thus, the differential influence systolic and 
diastolic blood pressure variables had on brain function by race, however minimal, may 
attenuate and/or cancel out when they are combined either within or across diverse 
populations. Differential involvement of indices associated with blood sugar control were 
also revealed when we stratified by race; i.e., long-term measures of control contributed to 
behavioral outcomes (depressive symptoms) in CAs while short-term measures of control 
contributed to cognitive outcomes (learning) in AAs. Although debate still exists on the 
presence of health disparities in hA1c levels [30], our result may reflect the functional 
impact of these possible differences [61]. Future studies emanating from these exploratory 
findings by race should focus on the role of minority health disparities in distinct blood 
pressure indices or distinct blood sugar metrics and/or their role in insulin resistance and the 
insulin network more broadly [59] on brain behavior relationships.
This study is not without limitations and by outlining them we hope they will point toward 
future research. Our sample was drawn from a larger study of diabetes. As such, our MetS 
groups differed in terms of their diagnosis, duration and control of diabetes, which resulted 
in a linear increase in these variables when moving from the no risk to the low risk to the 
high risk groups of our study. Despite this, we found non-linear associates to brain structure 
and function regardless of how we incorporated this particular MetS component as well as 
non-glucose related disease severity indices contributing to dysfunction when we stratified 
by race. Our investigation of relevant neuroanatomy revealed little and may have been 
negatively impacted by the gross volumetrics and/or select ROIs used in this study. An 
additional limitation of our work was that we did not divide our MetS groups by sex – 
primarily because of sample size limitations – however, considerations remain which are 
unique to women that may influence the number of MetS criteria met and/or disease severity 
of individual MetS components [62]. Likewise, investigating treatment regimens across 
MetS criteria groups, while critical to this work, requires a larger study than ours.
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CONCLUSION
This study revealed a profile of increasing depressive symptomatology when meeting 
increasing MetS criteria and a profile of learning and memory impairment when meeting 
any MetS criteria. The impact of health disparities in vascular risk were explored by 
investigating the contributions of disease severity of individual MetS components to these 
profiles by race. For example, results suggested a possible differential role for long- versus 
short-term measures of blood sugar control on affect and cognition based on CA and AA 
groups that should be investigated more directly in future research. Little to no impact was 
observed in global measures of relevant neuroanatomy; however, more subtle metrics of 
brain structure may be warranted to detect an impact of MetS risk in this diverse population. 
Overall, it appears there is a low threshold of metabolic risk for cognitive compromise in our 
sample of Caucasian and African Americans. This suggests we must incorporate a broader 
spectrum of subclinical CVD indices beyond those addressing the state or severity of one 
particular disease if we are to determine appropriate targets for risk modification and 
successful brain aging in adults from diverse populations.
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Table 1
Metabolic Syndrome (MetS) Group Characteristics
No Risk
(0 MetS criteria)
n=20
Low Risk
(1–2 MetS criteria)
n=60
High Risk
(3+ MetS criteria)
n=39
Group Characteristics
Age (years)a 53.5±14.2 62.8±12.4 60.6±12.3
Education (years) 15.5±3.1 15.3±2.7 14.1±2.4
Sex (M:F) 6:14 31:29 17:22
Race (B:W) 6:14 30:30 21:18
pVIQb 110.5±10.1 106.1±13.1 99.1±15.0
Diabetes Presence (%) 0% 31% 80%
Diabetes Duration (months) n/a 29.3±57.9 72.2±72.6
CIRSb 2.2±2.1 5.0±3.2 7.0±3.5
Criterion Met (%)
HDL 0 13 66
Glucose 0 36 66
HTN 0 66 77
Triglyceride 0 8 74
BMI 0 35 77
ap<.05;
bp≤.005;
M:F=male:female; B:W=black:white;
pVIQ=predicted verbal IQ; CIRS=Cumulative Illness Rating Scale.
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Table 2
Results of Multivariable Linear Regressions Examining the association of increasing MetS criteria on affect 
and cognition.
Affect Cognition‡
Variables
CES-D
B (SE)
LRN
B (SE)
MEM
B (SE)
ExFx
B (SE)
African American (vs White) 1.02 (1.24) −0.16 (0.18) −0.27 (0.17) −0.02 (0.14)
MetS Criteria Met
 1–2 vs 0 1.97 (1.12)T −0.39 (0.16)* −0.48 (0.16)** −0.24 (0.13)T
 3+ vs 0 4.73 (1.23)*** −0.42 (0.19)* −0.50 (0.18)** −0.12 (0.15)
 3+ vs 1–2 2.75 (0.89)** −0.03 (0.13) −0.02 (0.13) 0.12 (0.10)
NOTE:
***p<0.001;
**p<0.01;
*p<0.05;
Tp>0.05 and p≤0.10;
MetS=Metabolic Syndrome; 0=no risk, 1–2=low risk, 3+=high risk; CES-D=Center for Epidemiologic Studies of Depression; LRN=composite z-
score for Learning; MEM=composite z-score for Memory; ExFx=composite z-score for Executive Functioning. All analyses are adjusted for age, 
race, and pVIQ.
‡Cognitive outcomes were also adjusted for the CES-D.
Curr Alzheimer Res. Author manuscript; available in PMC 2016 March 11.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Lamar et al. Page 17
Table 3
Correlations between significant results of cognitive analyses and relevant neuroanatomical regions of interest.
Learning (LRN) Memory (MEM)
Relevant Neuroanatomy
Hippocampus r(74)=.33, p=0.004 r(74)=.32, p=0.005
Entorhinal Cortex r(74)=.17, p=0.148 r(74)=.21, p=0.064
Parahippocampal Gyrus r(74)=.33, p=0.004 r(74)=.35 p=0.002
Fusiform r(74)=.42, p<0.001 r(74)=.38, p=0.001
Note: All 2-tailed analyses are adjusted for age, sex, race, pVIQ as well as CES-D and met significance based on correction for multiple-
comparisons (p≤0.006).
Curr Alzheimer Res. Author manuscript; available in PMC 2016 March 11.
